American Society of Clinical Oncology (ASCO)

We join the oncology community in mourning the loss of translational research pioneer V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, on June 9, 2024. Read more: https://brnw.ch/21wKJ4l

Though there has been increased interest in using patient-reported outcomes, or PROs, as part of routine cancer care, barriers at the patient, clinician, and administrative levels have limited their implementation. Patient buy-in requires asking relevant and clinically useful questions, being sensitive to patient burden, and providing accessible options for PRO measure completion. Clinicians also experience their own barriers to PRO use. Traditional workflows require modifications to integrate PROs with clinic notes, laboratory results, and imaging findings. Workflows must present PRO data so that clinic discussions can focus on patients’ most relevant issues and support documentation requirements. As a result of these barriers, there is no one-size-fits-all PRO system. Each system must be adapted to the intended goals and resources available. For ASCO Daily News, a new expert editorial examines the potential for PRO use and the challenges involved: https://brnw.ch/21wKIXL

A key component to providing care is looking at a patient and their family holistically, which includes examining and intervening on patients’ behavioral health needs. ASCO’s Vice President of Care Delivery, Dr. Stephen Grubbs joins Dr. Sea Chen on the AMA Ed Hub podcast Steps Forward to discuss methods to integrate behavioral into oncology care. Listen now! Spotify: https://brnw.ch/21wKH3B Apple: https://brnw.ch/21wKH3A

A reminder that the request for proposals is open for medical institutions in low- and middle-income countries in the Central and Eastern Europe region to participate in our education and knowledge-exchange program, the International Cancer Corps (ICC). All proposals are due July 22. https://brnw.ch/21wKE9w

Our draft guideline, Transoral Robotic Surgery for Oropharyngeal Squamous Cell Cancer, is now available for open comment. Submit your feedback by June 19.  https://brnw.ch/21wKD6A

Check out our newly issued rapid recommendation guideline update on the Management of Stage III #NSCLC: https://brnw.ch/21wKD3n

Check out our new rapid guideline update on Systemic Therapy for Small Cell #LungCancer. These recommendations are considered provisional pending full text review of publication and confirmation of data. ➡️ https://brnw.ch/21wKCWY

Watch & share highlights from #ASCO24—available to the public! 🗣️ ASCO Voices 💬 Dr. Lynn Schuchter's Presidential Address 🎙️ How and Where Will Public Investment Accelerate Progress in Oncology? A Discussion with the NIH and NCI Directors 📣 The Lancet Commission on Women, Power, and Cancer: North American Launch 💊 Solving Decades of Drug Shortages in Oncology ...and more: https://brnw.ch/21wKzqa

ICYMI: Dr. Jyoti Patel breaks down new #ASCO24 research showing that consolidation therapy after chemoradiotherapy with durvalumab helps patients with limited-stage small-cell #LungCancer (LS-SCLC) live longer when compared to standard-of-care. See the science: https://brnw.ch/21wKwiq

The public and healthcare providers alike need to have accurate, digestible, and actionable information about cancer. We commend American Society of Clinical Oncology (ASCO) & American Cancer Society for their new partnership to provide a single online resource for credible, high quality cancer information on: http://cancer.org/. #Every1HasARole